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The release rate of doxorubicin (DOX) from the drug-delivery system (DDS), DC Bead, was studied by
2 miniaturized in vitro methods: free-ﬂowing and sample reservoir. The dependencies of the release
mechanisms on in vitro system conditions were investigated experimentally and by theoretical modeling.
An inverse relationship was found between release rates and bead size, most likely due to the greater
total surface area. The release rates correlated positively with temperature, release medium volume, and
buffer strength, although the release medium volume had larger effect than the buffer strength. The
sample reservoir method generated slower release rates, which described the in vivo release proﬁle more
accurately than the free-ﬂowing method. There was no difference between a pH of 6.3 or 7.4 on the
release rate, implying that the slightly acidic tumor microenvironment is less importance for drug
release. A positive correlation between stirring rate and release rate for all DDS sizes was observed,
which suggests ﬁlm controlled release. Theoretical modeling highlighted the inﬂuence of local equilib-
rium of protonation, self-aggregation, and bead material interactions of DOX. The theoretical release
model might describe the observed larger sensitivity of the release rate to the volume of the release
medium compared to buffer strength. A combination of miniaturized in vitro methods and theoretical
modeling are useful to identify the important parameters and processes for DOX release from a micro
gel-based DDS.
© 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.Introduction
In vitro investigations of drug release from drug-delivery sys-
tems (DDS) are of importance throughout the drug innovation and
development process.1 However, no standardized in vitro method
exists for parenteral systems, and as a consequence, there is a
diversity of in vitro methods.2,3 The in vitro release rate of doxo-
rubicin (DOX) from the microsphere DDS, DC Bead, has been
investigated in paddle, sample and separate, ﬂow through, and
T-cell methods.4-7 These in vitro methods use relatively large
amounts of DDS (1 mL) and release medium (200-900 ml).4,5,8
Miniaturized in vitro methods reduce the amounts of DDS sam-
ple, release medium and waste9,10; for example, to 20-65 mL (DDS
sample) and 10-20 mL (release medium).10 Another advantage of
the miniaturized method is that a low volume of release mediumfrom the authors by request
2016.08.011.
6-18-471-4317; Fax: þ46-18-
Lennern€as).
®. Published by Elsevier Inc. All rigmay be more relevant to the in vivo site in hydrodynamic and
diffusion properties.11-13 In this report, the in vitro release of DOX
from the beads was tested in 2 miniaturized methods. The beads
were loaded with DOX, a cytotoxic agent that is used in palliative
treatment of intermediate-stage hepatocellular carcinoma.14,15
DOX has a molecular mass of 543.52 g/mol and a LogD7.5 of
2.42.15 The pKas of DOX are 7.34, 8.46, and 9.46, and the compound
exists as both a deprotonated and protonated monovalent cation
at physiological conditions.16 The beads consist of polyvinyl
alcohol (PVA) with integrated, negatively charged 2-acrylamido-2-
methylpropanesulfonate (AMPS) units.17 Ion exchange has been
proposed as the mechanism for loading and release of protonated
DOX from the AMPS sulfonic acid groups.4,6,18 The beads are
nonbiodegradable, and the intrahepatic administration leads to a
local drug delivery in combination with a full and permanent
embolization of the treated hepatic arteries.4,14,17 In the clinic, the
beads are delivered by radiological image guidance with a
nonionic contrast medium, such as Omnipaque.4,14,19,20
The main objective of this study was to determine the
mechanism(s) and release rate of DOX from the beads. Second,
we investigated the effects of factors such as temperature, stir-
ring rates, buffer strength, pH, and volume of release mediumhts reserved.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-33983388on the in vitro release rate. Third, selected in vitro release proﬁles
were compared to an in vivo DOX-release data set. Finally,
the release mechansim(s) were investigated with theoretical
modeling.
Materials and Methods
Chemicals and DDS
DOX HCl salt was purchased from Toronto Research Chemicals,
Canada, and stock solutions were prepared by dissolving the DOX in
methanol (Millipore Corporation, Darmstadt, Germany). Three
buffers were used as release medium in the in vitro methods
(Table 1). Buffer I was phosphate buffer saline (PBS) prepared from
PBS tablets (Medicago, Uppsala, Sweden) with pH adjusted to 7.4
with 2 M HCl. Phosphate buffers II (pH 7.4) and III (pH 6.3) were
prepared from Na2HPO4 and NaH2PO4$H2O (Merck, Darmstadt,
Germany) as 100-mM solutions. The Naþ concentration was
adjusted by the addition of NaCl to buffer III to acquire equal mo-
larities of Naþ. Buffers II and III were diluted 10-fold for a ﬁnal
concentration 10 mM.
Two milliliters of each DC Bead (Biocompatibles UK, Ltd,
London, England) size (70-150, 100-300, and 300-500 mm) was
loaded with 25 mg/mL DOX per ml beads according to the
manufacturer’s instructions. Loading of 99% DOX into the beads
was considered complete after 30 min to 8 h, depending on bead
size, after which all of the loading solution except 2 mL was
discarded (i.e., 23 ml was discarded). This left a ﬁnal volume of 4
ml with a 50:50 ratio of beads and loading solution for use as
sample in all of the release experiments.19 For the quantiﬁcation
of the sulfur concentration in the beads, HNO3 (65%) and H2O2
(30%) (Merck), were used.
Experimental Design
A mDiss proﬁler (pION) was used to determine the in vitro DOX
release from the beads during various conditions (Table 1). The
drug concentration in the medium was determined as the area
under the concentration wavelength curve of the second derivate
spectrum at an interval of 553 to 572 nm. The application of the
second derivate spectrum reduces the background turbidity,
thereby enhancing peaks and reducing baseline shifting.21,22
Each channel was individually calibrated with the stock solu-
tions against a standard curve. All release studies were per-
formed under sink conditions (amount of DOX <10% of theTable 1
The Various Conditions Used in the Investigations of DOX Release From the Beads (DC B
Release Method Buffer Properties
Release Medium Buffer pH Buffer Streng
FF Buffer I PBS 7.4 10
FF Buffer I PBS 7.4 10
FF Buffer I PBS 7.4 10
SR 6 Buffer I PBS 7.4 10
SR 6 Buffer I PBS 7.4 10
SR 6 Buffer I PBS 7.4 10
SR 8 Buffer I PBS 7.4 10
Elution study Buffer I PBS 7.4 10
FF Buffer IIa NaPO4 7.4 10
FF Buffer IIb NaPO4 7.4 100
FF Buffer IIIa NaPO4 6.3 10
FF Buffer IIIb NaPO4 6.3 100
FF Buffer IIIb NaPO4 6.3 100
FF Buffer IIIb NaPO4 6.3 100
FF, free ﬂowing; SR 6, 6-mm sample reservoir; SR 8, 8-mm sample reservoir.
a In the elution study, 10 mL of the release medium was replaced with fresh buffer atsolubility), in 3 or more replicates, and the samples were pro-
tected from light with tinfoil during the experiments. The tem-
perature was kept constant during the release experiments using
a water bath.In Vitro Release of DOX From Beads in Free-Flowing Method
The free-ﬂowing in vitro setup is shown in Figure 1a. For each
experiment, 55 mL of beads was transferred into a glass vial con-
taining 20 mL of buffer I, at 37C. The in vitro drug release of DOX
from each of the 3 bead sizes was investigated at stirring rates of 0,
100, and 400 rpm. A Teﬂon-coated magnet for stirring was used
throughout the experiment.In Vitro Release of DOX From Beads in the Sample Reservoir Method
A modiﬁed sample reservoir (SR) method (adapted from the
study by Ahnfelt et al.10) is illustrated in Figure 1b. Discs with a
diameter of 22 mmwere manufactured (Loostec AB, Loos, Sweden)
in polyether ether ketone (PEEK) with a magnet (3.5  15 mm),
embedded inside the disc. The discs were manufactured with 2
different cylindrical cavities. SR 6 had a diameter of 6mm, a depth of
2 mm, and a cavity volume of 57 mL; SR 8 had a diameter of 8 mm, a
depthof 1mm, anda cavity volumeof 50mL. To avoid formationof air
bubbles, the cavity of SRs 6 and8was overloadedwith 60mL or 65mL,
respectively, of each bead size. A nylon mesh ﬁlter (Merck Millipore
Ltd, Darmstadt, Germany) with a pore size of 80 mmwas soaked in
deionizedwater for 10min at room temperature before use to retain
the beads in the SR. A PEEKplatewas placedon topof themeshﬁlter,
and a PEEK lid was used to assemble the sample holder. Two inte-
gratedwings (5.5 1 2mm) in the lid stirred the releasemedium.
Unless otherwise stated, 20mL of buffer I, at 37C and a stirring rate
of 400 rpm, was used throughout the experiment. In addition, the
DOX transport across the nylon mesh was examined with an
aqueous solution of DOX (2 mg/mL) in the 6-mm SR.Temperature
Other studies have reported that an increase in temperature
from 37C to 60C accelerates the in vitro release of drugs from
various DDS.23-26 We therefore investigated the effect of tempera-
ture at 37C, 47C, and 57C on the in vitro DOX release from the
100 to 300 mm beads in the free-ﬂowing method. Twenty milliliters
of 100 mM (buffer IIIb) was used.ead)
Method Properties
th (mM) Volume (mL) Stirring Rate (rpm) Temperature (C)
20 0 37
20 100 37
20 400 37
10 400 37
15 400 37
20 400 37
20 400 37
20a 400 37
20 400 37
20 400 37
20 400 37
20 400 37
20 400 47
20 400 57
predetermined time points.
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Figure 1. Two miniaturized in vitro methods: free ﬂowing (a) and sample reservoir (b). Both methods use the mDISS UV-dip probe to measure the drug release continuously. (a) In
the free-ﬂowing method, the sample is placed in a glass vial and stirred with a Teﬂon magnet. (b) In the sample reservoir method: (1) the sample is placed in the sample reservoir;
(2) the nylon mesh is mounted over the sample and a PEEK plate is attached, with a PEEK lid screwed on to the disc, and ﬁnally; (3) the sample holder is placed in the glass vial and
20 mL of PBS buffer is added.
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The impact of pH 7.4 or 6.3 on the in vitro drug release rate of
DOX from the 100 to 300 mm beads was investigated in the 8-mm
SR. Buffer II (10 and 100 mM) and buffer III (10 and 100 mM) were
each tested at pH 7.4 and 6.3. These 2 pH values were chosen for
their physiological relevance in the tumor microenvironment.27,28
Elution Study
To quantitatively compare the in vitro release data with corre-
sponding in vivo data, the maximum cumulative amount eluted
was measured.19 This was carried out with 65 mL of 100-300 mm
beads in the 8-mm SRs with 20 mL of buffer I as release medium. At
predetermined time points, 10 mL of the buffer was replaced with
fresh buffer, the stirring rate was set at 400 rpm, and the temper-
ature at 37C. The amount eluted was used to calculate the
maximum cumulative amount. This amount was then used to
calculate the in vitro DOX released (%) for comparison with
deconvoluted in vivo DOX release (%) data from the 100 to 300 mm
beads collected in a pig model.19
Release Medium Volume
The volume of release medium was adjusted to better simulate
the hydrodynamics and the in vivo volume available for drug
release. The DOX release from the 100 to 300 mm beads was
investigated with volumes of 10, 15, and 20 mL of buffer I and a
stirring rate of 400 rpm in the 6-mm SR. The percent DOX released
in vitrowas compared to the percent released locally in the liver in
the pig model.19
Determination of the Sulfur Concentration in the Beads
To determine the sulfur concentrationdwhich reﬂects the
amount of negatively charged gel network sites (SO3) in the
beadsdthe gel structure was degraded.29 Vials containing 2 ml
each of the 3 bead sizes were shaken to distribute the beads
homogeneously in the packing solution (approximately 6 ml of
1-mM PBS6,30,31). From each vial, 0.5 mLwas transferred to a 50-mLKjeldahl ﬂask to which 4.0-mL HNO3 (65%) and 2.0 mL H2O2 (30%)
were added. The degradation solutions were left to react for 1 hour
at room temperature, after which the ﬂasks were heated in an
aluminum block (105C) for 2 hours, then 145C overnight
(approximately 16 h). The degradation solutions were cooled to
room temperature, transferred to 15-mL tubes, and the volume
adjusted to 10.0 mL with Milli-Q water. Acid-matched calibration
solutions and a SPECTRO ciros CCD inductively coupled plasma-
atomic emission spectrometer (Spectro, Germany) optimized for
atom emission from sulfur at 182 nm were used for the quantiﬁ-
cation. The mean value of 3 consecutive integrations was recorded,
and for each bead size the degradation and quantiﬁcation were
performed in duplicate.Theoretical Model for DOX Release
The effect of stirring rates on DOX release in the free-ﬂowing
method was investigated to better understand relevant release
mechanism(s). Two theoretical release models were applied to the
DOX release proﬁles: (1) a ﬁlm control model in which the DOX
inside the beads remained homogeneous throughout the release
process and (2) an internal depletion-layer model in which DOX
was heterogeneously distributed inside the beads (Fig. 2a). Both
release models are based on the assumption that DOX forms
micelle-like aggregates inside the beads, which are in local equi-
librium with DOX monomers.23,32,33 The variation of bead volume
during release was neglected because previous release experi-
ments report only insigniﬁcant variation of the bead diameter
(100-300 mm) in the DOX-loading range.4,17 The variation increases
with increasing bead size but is rather small (<15%) even for the
300-500 mm beads. The theoretical fundamentals for each release
model are described in the following section.Film Control Model
In thismodel, the release rate is controlled by themass transfer of
released DOX molecules from the boundary of the beads, through
the stagnant layer, to the bulk of the release medium (Figs. 2a
and 2b). The rate of transferring n moles of DOX to the bulk liquid
is calculated from Equation 1:
ar 
r
r 
Internal depletion layerFilm control 
Dox 
aggregates 
Shell
Dox 
aggregates 
Core
Bead 
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Stagnant 
layer 
b
C'
C
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Figure 2. (a) Assumptions made for the theoretical modeling of the doxorubicin (DOX) release from the beads (DC Bead) in the free-ﬂowing method. Left: in the ﬁlm control model,
the DOX is considered to have DOX aggregates homogenously distributed throughout the bead and the aggregates are in equilibrium with DOX monomers in the stagnant layer.
Right: in the internal layer-depletion model, the release rate is considered to be governed by diffusive mass transfer from heterogeneous beads consisting of a core with DOX
aggregates and a shell with DOXmonomers. (b) Assumptions of the ﬁlm control model, where C is the concentration of DOX monomeres; C0 is the concentration of DOX monomeres
inside the bead; r is the bead radius; and Cbulk(0), Cbulk(t), and Cbulk(∞) are the DOX concentrations in the bulk at time zero, time t, and inﬁnite time, respectively.
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dn
dt

ss
¼ 4pr2ktðC  CbulkÞ ¼ 2prShDðC  CbulkÞ (1)
where r is the bead radius, kt is the mass transfer coefﬁcient, Sh is
the Sherwood number, D is the diffusion coefﬁcient in the liquid,
and C and Cbulk the concentration of DOX in the liquid at r and in the
bulk, respectively. The second equality was obtained by using the
relationship: Sh ¼ 2rkt/D. Sh is related to the Reynolds (Re) and
the Schmidt (Sc) numbers:
Sh ¼ 2:0þ 0:6Re1=2Sc1=3 (2a)
Sh ¼ 2:0þ 0:47Re0:62Sc0:36ðdS=dTÞ0:17 (2b)
Re ¼ 2vrr
h
(2c)
Sc ¼ h
rD
(2d)
where v is the ﬂow rate of the liquid relative to that of the bead, r is
the particle density, and h is the liquid viscosity. Equation 2a is valid
as a good approximation for single spheres under conditions of
forced convection at moderate ﬂow rates (Re<20).34 Equation 2b is
the Levins-Glastonbury correlation of for particles in an agitated
vessel, where ds and dT are the diameter of the stirrer and the tank,
respectively.35 In the limit as v/0, Sh approaches the value 2 in
both expressions, the right hand side of Equation 1 becomes
identical to the expression for the diffusive transport from the
surface of a sphere in an inﬁnitely large ﬂuid volume with con-
centration Cbulk.34
Film control implies that the relaxation time of all processes
inside the beads is short and thus that the internal distribution of
all species is uniform. DOX monomers and all other mobile species
in the beads are assumed to be in local equilibrium with the liquid
solution. By neglecting activity coefﬁcients, we have:
C2salt ¼ C0þC0 (3)
CCsalt ¼ C0C0 (4)
Cp þ C0 ¼ C0 þ C0mic þ C0þ (5)where Csalt is the concentration of 1:1 electrolyte in the solution,
and C0þ and C0 are the concentrations of positive and negative salt
ions in the gel beads, respectively. C0 is the concentration of DOX
monomers in local equilibriumwith micelles inside the beads, C0mic
is the concentration of DOX in micelles, and Cp is the concentration
of ﬁxed network charges in the beads; Cp ¼ 3np=ð4pr3Þ, where np is
the number of moles of network charges per bead. Equations 3 and
4 ensure that the chemical potential of mobile electrolytes is the
same on both sides of the boundary, and Equation 5 is the condition
of local electroneutrality. C0 is treated as a constant equal to the
critical micelle concentration of DOX in the beads, and the effective
ﬁlm thickness (¼ 2r1=ðSh 2Þ) is constant. However, C, which is
regulated by the relationships Equations 3-5 and Cbulk changes
during the release process. This means that the analysis is based on
the assumption that pseudo steady states exist in the ﬁlm, a com-
mon approximation in models of controlled release.36
By neglecting the amount of DOX in the stagnant layer sur-
rounding each bead (an excellent approximation in the present
systems), the concentration in the bulk is directly related to the
amount n released: Cbulk ¼ n=V , with V being the volume of the
solution. From Equations 1-5, the time needed to release an
amount nt can be described by Equation 6:
t ¼
Znt
0
f2prShDðC  CbulkÞg1 dn (6)
Internal Depletion-Layer Model
In this model, a depletion layer free from DOX aggregates is
formedwithin thebeadsduring the releaseprocess (Fig. 2a). The core
of the bead has the same composition as the initially homogeneous
bead. During the release process, DOX is transported through the
depletion layer from the core boundary at a distance rc from the
center of the beads to the gel boundary r and from the gel to the bulk
liquid. The last step is described by Equation 1, in analogy with the
ﬁlm control model. During release, r is assumed to be constant
whereas the core boundary migrates inwards. DOX transport
through the depletion layer is described as binary diffusion inwater,
an assumption valid when there is an excess of simple salt.37 The
process is analogous to the dissolution of solid particles in a polymer
matrix, and following Higuchi,38 the analysis is based on the pseudo
steady-state assumption, which in this case means that the con-
centrationproﬁle in the depletion layer is always at steady statewith
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-3398 3391respect to themovementof the core boundary. The latter assumption
is justiﬁedas theDOXconcentration in thecore ismuch larger than in
the shell.36 The transport rate of DOX through the shell is given by:

dn
dt

ss
¼
4prcrDs

C
00  C 00c

r  rc (7)
with Ds being the diffusion coefﬁcient in the shell and C
00
and C
00
c the
concentrations of DOX monomers in the shell and at the core
boundaries, respectively (Fig. 2a). At steady state, the transport rate
is the same in the shell and the ﬁlm. Equations 1 and 7 can then be
combined to give:
rc
r  rc ¼
DShðC  CbulkÞ
2Ds

C 00  C 00c
 (8)
The conditions corresponding to Equations 3-5 for local equi-
librium at the bead boundary are:
C2salt ¼ C
00
þC
00
 (9)
CCsalt ¼ C
00
C
00
 (10)
Cp þ C 00 ¼ C
00 þ C 00þ (11)
where C
00
þ and C
00
 are the concentrations of positive and negative
salt ions, respectively, in the shell at r. By neglecting the amount of
DOX in the shell and the ﬁlm, rc is directly related to r and the
concentration of DOX accumulated in the bulk:
rc
r
¼

C*  Cbulk
C*
1=3
(12)
where C* is the total concentration of DOX in the system
(beads þ liquid). Given the parameter set fC 00c ;Cp; Cbulk;C*g,
Equations 8-12 can be used to calculate an unknown set
fC;C 00 ;C 00þ; C
00
 g. This set can then be used in Equation 6 to calculate
the time to reach a concentration Cbulk in the bulk.Poisson-Boltzmann Cell Model and Dimerization Model
To investigate what effect salt addition might have on the
equilibrium between protonated and deprotonated DOX, we used
the Poisson-Boltzmann (PB) cell model approach to amphiphilic
self-assembly.39 This model, which has been very successful in
accounting for properties of surfactant micelles and phase
behavior, is described in detail in Supporting Information S1. In
brief, DOX inside the beads is assumed to form cylinder-shaped
aggregates in equilibrium with dispersed monomers.40 The pro-
tonated (Dþ) and deprotonated (D0) forms of DOX are assumed to
occupy the same volume in the aggregate and the same area at the
aggregate surface. The PB equation is used to calculate the distri-
bution of ions in the aqueous domains between the cylinders. All
ions are equilibrated between the gel and the surrounding solution,
except the network charges. The local equilibrium between the
protonated and deprotonated forms (Dþ#D0 þ Hþ) is described
using pKa ¼ 8.46. The total concentration of DOX in the system (gel
and solution) is equal to that in the free-ﬂowing experiments
(0.063 mM). The solution has a ﬁxed pH of 7.4 and contains either
10 or 100 mM of a monovalent salt. All other parameters in the
calculations are given in Supplementary Table S1.
To investigate the effect of dimerization of DOX in the solution,
we used a dimerizationmodel which provides a qualitative account
of the aggregation of DOX. By letting K denote the equilibriumconstant for dimerization, the concentration of dimers becomes
equal to KC2 and the total concentration of DOX in the solution
becomes equal to 2KC2þC, where C is the monomer concentration.
Data Analysis
Various in vitro parameters (such as applied method, stirring
rate, temperature, pH, and volume of release medium) were
analyzed (GraphPad Prism 6.04; GraphPad Software, Inc.), for their
effect on the release rate constant. The one-phase association
(Eq. 13) was used as follows:
A ¼ Amax  ð1 exp ð  krel  tÞÞ (13)
where A is the amount released after time t (at time 0 Awas set to
0), Amax is the maximum amount released, and krel is the estimated
release rate (time1). To estimate krel, Equation 13 was ﬁtted to the
mean observed value at each time point of the in vitro data. Sta-
tistical comparisons of the release rates were performed with
multiple analysis of variance with Tukey's correction for multiple
comparisons (GraphPad Prism 6.04, GraphPad Software, Inc.).
Results were considered signiﬁcant if p < 0.05.
An approximation of the relative total surface area of each bead
size (70-150, 100-300, and 300-500 mm) was calculated using the
total number of beads per vial reported by the manufacturers:
1,300,000; 200,000; and 38,000, respectively. The radius of the
loaded beads was calculated from reported data.6,8,17 The total
surface area of one vial of beads was calculated to be 6.8, 3.5, and
2.6 cm2, respectively, for the 3 sizes of beads, that is, a ratio of
2.6:1.3:1.
The goodness of ﬁt of in vitro data to be reported in vivo datawas
expressed as the absolute average fold error (AAFE), Equation 14.
Absolute average fold error ¼ 10
Plog PredictedObserved

N (14)
AAFE describes the geometric mean ratio of the predicted and
observed values, and N is the number of observations. An AAFE
value of <1.25 was considered a good ﬁt, 1.25-2.0 adequate, and
>2.0 poor.
Both of the theoretical models, namely the ﬁlm control and
internal depletion-layer models, contain 2 unknown parameters:
the concentration of monomers in local equilibrium with the
micelles inside the beads, C0 (ﬁlm control) and C 00c (internal deple-
tion), and the Sherwood number (Sh). Theoretical model curves
were ﬁtted to experimental datawith the 2 unknowns as adjustable
parameters. Equations 2a-2d were used to calculate the ﬂow rate of
the liquid relative to the beads (v) from the determined Sh values.
The models were evaluated based on visual inspection as well as
the appropriateness of the estimated parameters. The parameters
set by the composition of the system are displayed in Table 2.
Results
DOX Release From Beads in the Free-Flowing Method
The estimated in vitro DOX release rates from the beads in the
free-ﬂowing method at stirring rates of 0, 100, and 400 rpm and of
the SR method are shown in Figure 3a. Their release rates and
their differences are listed in Table 3. In the free-ﬂowing method
with a stirring rate of 100 rpm, the release rate (krel) from the 70 to
150 mm beads was signiﬁcantly different (4.1 h1, p < 0.05) from
those of the 100-300 (1.9 h1) and 300-500 mm (1.6 h1) beads
(Fig. 3a and Table 3). At a stirring rate of 400 rpm, the release rate
for the 70-150 mm beads was also signiﬁcantly different (p < 0.05)
Table 2
Fixed Parameters for the Theoretical Release Models of DOX From The Beads
(DC Bead)
r 50, 100, and 200 mma
Cp 14.2, 15.8, and 18.6 mMa
C0 92 mM
C* 0.063 mM
Csalt 100 mM
D 2.1$1010 m2/sb
Ds 2.1$1010 m2/s
r: bead radius; Cp: concentration of ﬁxed network charges in the beads; C0: con-
centration at time zero; C*: is the total concentration of DOX in the system (beads
and liquid); Csalt: is the concentration of 1:1 electrolyte in the solution; D: is the
diffusion coefﬁcient of DOX; and Ds: is the diffusion coefﬁcient of DOX in the shell.
a Representing fractions with bead diameters 70-150, 100-300, and 300-500 mm,
respectively.
b From the study by Biondi et al.45
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-33983392from the rates for the large-sized beads (100-300 and 300-500
mm), that is, release rate increased with reduced bead size
(Fig. 3a and Table 3). The release rates of DOX from the 70 to 150
mm beads increased signiﬁcantly (p < 0.05) from 1.8 h1 without
stirring to 4.1 h1 (at 100 rpm) and 5.3 h1 (at 400 rpm).
The relation between the estimated release rates, krel, and the
relative total surface area in the free-ﬂowing method is shown in
Figure 3b. If y equals the release rate (h1), the correlation
between x (the relative total surface area) and the release rate was
y ¼ 0.49  x þ 0.52, R2 ¼ 0.99, (for 0 rpm), y ¼ 1.6  x e 0.11,
R2 ¼ 0.99 (for 100 rpm) and y ¼ 2.1  x e 0.15, R2 ¼ 0.99 (for
400 rpm).DOX Release From the Beads in the SR Method
Figure 3a shows the in vitro release rates of DOX from the beads
in both the 6- and 8-mm SRs as well as the free-ﬂowing methods
with a stirring rate of 400 rpm. For all bead sizes, the corresponding
DOX release rates were signiﬁcantly lower (p < 0.05), in the 6-mm
SRs than in the free-ﬂowing method (Table 3). In addition, the
release rates in the 6-mm SR were signiﬁcantly lower (p < 0.05)
than in the 8-mm SRs except for the 300-500 mm beads (Table 3).0
2
4
6
8 70-150 µm
100-300 µm
300-500 µm
SR
8 400 rpm
FF 400 rpm
FF 100 rpm
FF 0 rpm
Release rate
(h-1)
SR
6 400 rpm
R
a b
Figure 3. (a) Impact of in vitromethod, that is free-ﬂowing (FF), 6-mm sample reservoir (SR
phosphate buffer saline (PBS), (20 mL, pH 7.4, 37C). The in vitro DOX release from 3 bead siz
3 bead sizes in free-ﬂowing method (20-mL PBS buffer, pH 7.4, 37C). For stirring rates of 0
surface area, is y ¼ 0.49  x þ 0.52, R2 ¼ 0.99; y ¼ 1.6  x  0.11, R2 ¼ 0.99; and y ¼ 2.1 The release of DOX from the aqueous solution reached Amax
within 1 min (data not shown), indicating a rapid passage of DOX
across the nylon mesh.
Impact of Temperature
The impact of the temperature of the release medium on the
in vitro DOX release from the 100 to 300 mm beads in the free-
ﬂowing method is shown in Figure 4a. Temperatures of 37C,
47C, and 57C generated release rates of 0.063, 0.082, and 0.19
(min1), respectively (Fig. 4a). The correlation between release
rate in min1 (x) and temperature in C (y) can be given as
y ¼ 0.0065  x e 0.19 with a R2 of 0.86 (inset Fig. 4a).
Impact of pH and Buffer Strength on Release Rate
Table 4 shows the effects of changes in pH and buffer strength
on the estimated release rates (h1) and amount of DOX released,
Amax (mg) from the 100 to 300 mm beads in the 8-mm SR. There was
no signiﬁcant difference in release rates at pH 7.4 and 6.3. However,
signiﬁcant differences (p < 0.05) were observed when the NaPO4
buffer strength was reduced from 100 mM to 10 mM. This resulted
in a 70% reduction in released amount DOX at pH 7.4 and an 80%
reduction at pH 6.3.
Impact of the Volume of Release Medium on DOX Elution
The cumulative amount of DOX eluted from the 100 to 300 mm
beads in the 8-mm SRwas 911 mg after 49 hours (Fig. 4b). Assuming
that the 65-mL sample contained a 50:50 ratio of bead and loading
solution, the maximum amount of DOX that could possibly be
released would be 812.5 mg, the 911 mg thus generated a recovery of
112%. The effect of release method on DOX release was investigated
on the 100-300 mm beads, and the results (Figs. 5a and 5b and
Table 5) were compared to the observed in vivo DOX release from
100 to 300 mm beads in the pig model.19 The SR method described
the in vivo data with higher accuracy (AAFE <1.27) than the free-
ﬂowing method (AAFE 3.62). In addition, a reduction in release
medium volume from 20 to 15 and 10 mL in the 6-mm SR method0
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6) or 8-mm sample reservoir (SR 8), on in vitro doxorubicin (DOX) release from beads in
es is shown at 3 stirring rates. (b) DOX release rate and relative total surface area for the
, 100, and 400 rpm, the correlation between y, release rate (h1), and x, relative total
x  0.15, R2 ¼ 0.99, respectively.
Table 3
Determined Release Rate, Krel (h1) Presented as Mean (±SD) of DOX Release From
Selected Sizes of the Bead (DC Bead) in 2 In Vitro Methods
Method rpm 70-150 mm,
k (h1)
100-300 mm,
k (h1)
300-500 mm,
k (h1)
FF 0 1.8 ± 0.11a,b 1.2 ± 0.036 1.0 ± 0.12
FF 100 4.1 ± 0.33a,b,w 1.9 ± 0.098 1.6 ± 0.057w
FF 400 5.3 ± 0.64a,b,w,x 2.4 ± 0.46w 2.1 ± 0.31w
SR 6 400 0.35 ± 0.031b,y 0.32 ± 0.02b,y 0.87 ± 0.066y
SR 8 400 0.88 ± 0.049a,y,z 1.3 ± 0.15b,y,z 0.82 ± 0.064y
Level of signiﬁcance p < 0.05: adifferent from 100 to 300 mm; bdifferent from 300 to
500 mm; wdifferent from FF 0 rpm; xdifferent from FF 100 rpm; ydifferent from FF
400 rpm; zdifferent from SR 6.
FF, free ﬂowing; SR 6 and SR 8, 6-mm and 8-mm sample reservoir.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-3398 3393resulted in a decrease in AAFE from 1.27 to 1.09 and 1.08, respec-
tively. In conclusion, the 6-mm SR with 10 mL of release medium
most accurately described the in vivo release of DOX from 100 to
300 mm beads.
Sulfur Concentration in the Beads
The concentration of sulfur showed a trend of increased con-
centration with increasing bead size with the beads of 70-150,
100-300, and 300-500 mm having mean concentrations of 56.6,
62.6, and 74.3 mg/mL, respectively.
Theoretical Model of DOX Release
For each bead size, the experimental data points were
collected in the free-ﬂowing method at 3 different stirring rates
(0, 100, and 400 rpm). All experimental curves had a more or less
well-developed plateaus at later times (>4 h), indicating that the
systems reached equilibrium during the experiment. In both the
ﬁlm control and internal depletion-layer models, the plateaus
were affected by C0 and C 00c , respectively, but not by Sh. This means
that the parameters can be accurately determined independently
of each other. The ﬁlm control model ﬁtted all data sets
(Table 6 and Fig. 6). For a given stirring rate, Sh increased with
increasing bead size. This is as expected since larger beads should
have a lower speed than smaller ones in the liquid and, therefore,
a higher velocity relative to the liquid medium. Shown in Table 6
are also the liquid ﬂow rates v calculated from Sh. The values0 10 20 30 40
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Figure 4. In vitro doxorubicin (DOX) release from 100 to 300 mm beads. (a) The impact of
(400 rpm). Inset shows correlation between release rate (y) and temperature (x) where y ¼ 0
(pH 7.4 and 37C) under stirring (400 rpm) shown as cumulative amount (mg) released. At
amount (mg) DOX released.calculated from Equation 2b, a correlation valid for particles in an
agitated vessel, are probably more accurate than those calculated
from Equation 2a, valid for single spheres under conditions of
forced convection. However, in no case of applied stirring, and
irrespective of correlation used, did the v-values exceed the
theoretical upper limit set by the rotational speed of the magnetic
stirrer, which for a 2-cm stirring bar would be 0.1 m/s at 100 rpm
and 0.5 m/s at 400 rpm (Table 6). Finite but small v values were
also obtained when there was no applied stirring (0 rpm). This
is expected since convection is difﬁcult to avoid in practice.
The internal depletion-layer model adequately described the
release of DOX from 70 to 150 and 100 to 300 mm beads
(Table 6 and Fig. 6), but for the 300 e 500 mm beads, it did not
capture the release proﬁle.
Figure 7 shows the result obtained by combining the dimer-
ization model with the PB cell model calculations. Two scenarios
were considered: (A) beads with the initial DOX content in local
equilibriumwith the solution at the start of the release experiment;
and (B) beads in equilibrium with the solution at the end of the
release experiment. Both at the start of the release experiment
(case A) and the end of the release experiment (case B), the mole
fraction of Dþ in the aggregates (xDþ ) was below 0.5 at both salt
concentrations, indicating that the deprotonated form dominates
in the aggregates even when the protonated form completely
dominates in the solution. The result is valid for K ¼ 0 (10 mM salt)
and K¼ 100 mM1 (100 mM salt), meaning that dimerization takes
place only at the higher salt concentration, for which it starts at
DOX concentrations in the lower mM range, in agreement with
literature data.41 Decreasing the salt concentration from 100 to 10
mM reduced the maximum fraction released from 0.4 to 0.2, in
qualitative agreement with the reduction observed in the SR
experiments (Table 4).
Discussion
The release rates of DOX from the 3 bead sizes (70-150, 100-300,
and 300-500 mm) were investigated in 2 miniaturized in vitro
methodsdthe free ﬂowing and the SR. In the free-ﬂowing method,
the DOX release from the beads increased with higher relative total
surface area (Fig. 3b) in good agreement with the literature.5
Interestingly, DOX release rates were more reduced in the 6-mm
SR method than in the free-ﬂowing method for all 3 bead sizes.
Since the passage of DOX across the nylon mesh was too rapid0 10 20 30
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temperature in 20 mL of 100-mM NaPO4 pH 6.3, free-ﬂowing method under stirring
.0065  x  0.19, R2 ¼ 0.86. (b) Elution study in 20 ml of phosphate buffer saline (PBS),
predetermined times, 10 mL of the buffer was replaced with fresh buffer. Inset shows
Table 4
In Vitro Release Rates, Krel (h1) and Amax (mg), Presented as Mean (±Standard De-
viation) of DOX From 100 to 300 mm Beads (DC Bead), Investigated 20 mL of Release
Medium With Tumor-Relevant pH and of 2 Selected Buffer Strengths in the 8-mm
Sample Reservoir
Release Medium Buffer IIa Buffer IIb Buffer IIIa Buffer IIIb
krel (h1) 0.86 ± 0.036 1.4 ± 0.16 0.93 ± 0.037 1.0 ± 0.050
Amax (mg) 110 ± 1.1 370 ± 7.9 80 ± 0.73 410 ± 4.4
Buffer IIa; pH 7.4 and buffer strength 10 mM.
Buffer IIb; pH 7.4 and buffer strength 100 mM.
Buffer IIIa; pH 6.3 and buffer strength 10 mM.
Buffer IIIb; pH 6.3 and buffer strength 100 mM.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-33983394(<1 min) to have any major impact on DOX release, this could not
explain the release rate reduction observed in the 6-mm SR. A
possible explanation might be that the packing or the conﬁnement
of the beads in the SR affected the DOX release rate, as previously
shown by Carugo et al.42 Furthermore, the release rate of DOX from
the beads was positively correlated to higher stirring rates in the
free-ﬂowing method (Fig. 3a and Table 3). These results were also
evaluated in the theoretical releasemodels, whichwill be discussed
in following sections.
Temperatures of 47C and 57C had up to 3 times higher release
rates then 37C (Fig. 4a), in line with previous reports of DOX
release from ion exchange resins.26 The proposed mechanisms for
these results is a positive correlation of temperature dependency
and the diffusion rate of DOX, which would affect the Brownian
motion of the molecule.23,43-46 These results are of importance as
increasing the temperature can reduce the evaluation time in the
development process. However, mechanistic conclusions drawn
from accelerated studies are only valid if the release mechanism is
the same as in real-time investigations.12
The pH in an in vivo tumor environment varies between 6.0 and
7.0.27,28 DOX release from 100 to 300 mm beads was the same for a
pH of 6.3 as for a pH of 7.4 in the release medium (Table 4). This
suggests that microenvironment pH in and around the tumor is not
a direct factor in the intraindividual and interindividual variability
in tumor response to these beads when loaded with DOX.
Since themechanism of drug release has been proposed to be by
ion exchange, the concentration of Naþ-ions is expected to have a
signiﬁcant impact on the in vitroDOX release. It has been previously
reported that ionic strength inﬂuences the DOX release from the
beads, which also was conﬁrmed in this study (Table 4).5 The2
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Figure 5. Comparisons of the doxorubicin (DOX) release from 100 to 300 mm beads in the in
proﬁles were collected in phosphate buffer saline (PBS), pH 7.4, 37C under stirring (400 rpm
(SR 8) in 20-mL PBS. (b) The effect of volume of release medium with SR 6 in 10-, 15-, andimpact of ion concentration on the in vitro release of DOX from the
beads is discussed in detail in the following sections, but the effect
of cations in the tumor microenvironment on the local in vivo
release of DOX remains to be investigated.
In the elution study, the maximum amount of DOX released was
812.5 mg, and the cumulative amount of DOX released was 911 mg
(Fig. 4b). The recovery was 112%, which corresponds to a laboratory
transferring error of approximately 3 mL of beads. A volume of
10-15 ml of release medium most accurately described the local
hepatic in vivo proﬁle (Figs. 5a and 5b and Table 5). A low volume of
release medium in the in vitro method might be more relevant to
the in vivo situation, since the volume available for drug release at
the site of target is typically low.12,13 The effect of the lower volume
might be explained by altered diffusion rate and the hydrody-
namics at the in vivo site. The packing or conﬁnement of the beads
might also inﬂuence their release of DOX which would account for
the more in vivoelike release proﬁle of the SR method than the
free-ﬂowing method.42
The release proﬁles from the free-ﬂowing method at 3 stirring
rates (0, 100, and 400 rpm) were evaluated with the 2 theoretical
models, ﬁlm control and internal depletion layer (Figs. 2a and 2b).
For all 3 bead sizes, the more accurate model was ﬁlm control. The
internal depletion-layer model accurately described the release
from 70 to 150 and 100 to 300 mm beads, but in the latter case, the
values of the liquid ﬂow rate vwere high; the value calculated from
Equation 2a was close to the theoretical upper limit at 100 rpm,
which is unrealistic since it implies that the gels do not move in the
liquid. For 300-500 mmbeads, the quality of the ﬁt with the internal
depletion-layer model was very poor, both at 100 and 400 rpm
(Fig. 6), and the estimated values of v were not within the theo-
retical limits. The model could not reproduce the shape of the
release curves for beads in that size range for any Sherwood
number, not even when the ﬁlm thickness was reduced to zero
(i.e., by letting Sh / ∞). Reasonably good ﬁts could only be
obtained at early time points with values corresponding to ﬂow
rates (v) equal to, or larger than, the theoretical limit and by
accepting very poor ﬁts at later times. Recall that the internal
depletion-layer model describes mass transfer from the bead
boundary to the bulk solution in the same way as the ﬁlm control
model. Thus, for sufﬁciently large beads, for which the internal
diffusion length is comparable to, or larger than, the stagnant layer
thickness, the internal depletion-layer model is expected to
describe the release proﬁles better than the ﬁlm control model.0 2 4 6
0
0
0
0
0
0
Time (h)
In vivo 10 ml 20 ml15 ml
vestigated in vitro methods to observed in vivo data from a pig model.19 In vitro release
). (a) Free-ﬂowing (FF), 6-mm sample reservoir 6 (SR 6) and 8-mm sample reservoir 8
20-mL PBS.
Table 5
Estimated In Vitro Release Rates, Krel (h1) and Amax (%), Presented as Mean ±
Standard Deviation (±SD) of DOX from 100 to 300 mm Beads
Method Volume (mL) krel (h1) Amax (%) AAFE
In vivoa e 0.62 ± 0.11 31 ± 2.3 e
SR 6 10 0.56 ± 0.049 30 ± 0.73 1.08
SR 6 15 0.51 ± 0.038 35 ± 0.81 1.09
SR 6 20 0.47 ± 0.046 42 ± 1.3 1.27
SR 8 20 1.2 ± 0.17 28 ± 0.78 1.21
FF 20 2.4 ± 0.46 69 ± 2.1 3.62
The in vivo relevance investigated with sample reservoir 6 and 8 mm (SR 6 and SR 8,
respectively) and free ﬂowing (FF). For SR 6, the release medium volume is in the
interval of 10 to 20 mL.
a Reported in vivo data from a pig model.19
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-3398 3395Since, in fact, the contrary was observed, our results suggest that
the DOX release rate is not limited by internal transport processes
but is instead controlled by ﬁlm diffusion. The same conclusionwas
also reached by Biondi et al.6 in a recent paper. However, we stress
that there are important differences between their analysis and the
one presented here. For ﬁlm diffusion control, they used a pseudo
steady-state approach similar to the one used by us,47 but DOX was
assumed to be uniformly dispersed as monomers inside the beads.
Local equilibriumwas assumed at the bead boundary, whichmeans
that the concentration gradient in the ﬁlm decreased as the con-
centration inside the beads decreases. The particle diffusion model
employed48 allowed diffuse concentration gradients to develop
inside the beads during release but again assumed that DOX is
dispersed as monomers. In contrast, our models allow a large
fraction of DOX to be aggregated inside the beads and take into
account how that affects both the transport kinetics and the con-
centration of DOX in the solution required to reach equilibrium
with the beads. In particular, in our ﬁlm control model, the DOX
concentration in the ﬁlm at the bead boundary remains low and
constant even though the total DOX concentration inside the beads
changes considerably. Furthermore, whereas Biondi et al. treat the
solution as a sink, we take into account that the solution has a ﬁnite
volume. The difference is important, as in our models the concen-
tration in the solution is allowed to reach the concentration at
which the solution is in equilibrium with the beads at a fraction
released lower than 100%. In order to fully assess the relevance of
the present models, the physical basis behind them is described in
the following section.
Both the loading efﬁciency and the release kinetics are expected
to be determined by the aggregational state of the cationic
amphiphile DOX, a compound with well-documented amphiphilic
and self-assembling properties.23,32,33 It dimerizes in very diluteTable 6
Results From Model Fitting to Free-Flowing (FF) DOX Release Data (pH 7.4, 37C)
d (mm) Stirring
Rate
(rpm)
Film Control Internal Depletion Layer
v (mm/s) C0 (mM) Sh v (mm/s) C 00c (mM) Sh
100 0 1.3 (0.76) 21.5 4.96 e e e
100 100 8.6 (8.0) 21.5 11.6 36 (48) 28.5 25.4
100 400 12 (12) 21.5 13.6 36 (48) 28.5 25.4
200 0 4.8 (4.6) 23 12.3 e e e
200 100 12 (14) 18 19.9 71 (129) 24.3 56.4
200 400 18 (23) 20 24.9 106 (212) 27.1 71.7
400 0 31 (54) 13.5 51.9 Poor ﬁt
400 100 49 (96) 14.5 68.2 Poor ﬁt
400 400 95 (218) 16.5 102 Poor ﬁt
d: bead diameter; rpm: rotations per minute; Sh: Sherwood number; v: liquid ﬂow
rate calculated from Equation 2b (values in parenthesis calculated from Eq. 2a);
C’ and C
00
c are the concentration of DOXmonomers in local equilibrium with micelles
inside the beads for ﬁlm control and internal depletion-layer models, respectively.solutions (~106 M), and the aggregation number increases pro-
gressively with increasing concentration, reaching very high values
in the more concentrated solutions. For instance, at concentrations
comparable to those inside the beads (~100 mM), rod-like micelles
form.40 Aggregation inside the beads would affect the loading
(entrapment) efﬁciency, the release kinetics, and the maximum
amount (dose) that can be released.
The beads contain negatively charged AMPS as an integral part
of the network.17,18 During loading, DOX replaces network coun-
terions; during release, DOX is replaced by counterions entering
from the elution medium.45 However, this ion-exchange mecha-
nism can only partly explain the total loading and release of DOX.
First of all, the nearly quantitative replacement of simple counter-
ions by DOX during loading shows that there are additional non-
electrostatic driving forces present.45 One such force would be the
hydrophobic interactions between DOX molecules that are also
responsible for the self-association of DOX in solution. A cardinal
feature of ionic surfactant-polyelectrolyte systems is that micelles
appear at a much lower surfactant concentration than in polymer-
free solutions.49 The charged polymers screen the electrostatic
repulsion between the surfactant head groups so that micelles can
form without the entropic penalty of binding a large number of
simple counterions. Instead, entropy is gained by the release of
counterions bound to the polymer. The same principle explains the
strong binding of ionic surfactants to oppositely charged polymer
networksdthis binding provides a strong driving force for the
uptake of DOX by the beads at lower loading levels.50 However, the
situation changes once the DOX/network charge ratio in the beads
exceeds unity. Above unity, the electrostatics counteract binding
since it must be accompanied by cobinding of negative ions for the
beads to remain net electroneutral, a process lowering the entropy
of the system. In our measurements, the charge equivalence
between DOX and AMPS corresponded to 4.4 mg DOX per mL of
beads. However, in the release experiments the beads initially
contained 25 mg/mL and the maximum loading capacity has been
reported to be as high as 45 mg/mL.4 Clearly, the ion exchange
mechanism alone cannot account for such high intrabead concen-
trations of DOX.
We believe there are 3 contributions to the high-loading
capacity of DOX in the beads: the hydrophobic interaction
between the DOX molecules, the hydrophobic interaction between
DOX aggregates and PVA chains inside the beads, and the possi-
bility of DOX to regulate its charge. The ﬁrst of these, the hydro-
phobic interaction between DOX molecules, promotes excess
binding but by itself appears unable to overcome the entropic
penalty of cobinding the counterions (25 mg DOX/mL requires
cobinding of approximately 130-mM chloride ions) unless sub-
stantial amounts of salt are present, as shown by the behavior of
related surfactant-gel systems.51
The second contribution derives from the fact that PVA is an
amphiphilic polymer known to bind to the surface of regular
cationic surfactant micelles in aqueous solution thereby stabilizing
them.52,53 According to Lewis et al.,17 the beads contain 96 wt%
water when in equilibrium with pure water. By subtracting the
weight fraction of AMPS (16 mM corresponds to 0.5 wt%), we found
that the 100-300 mm fraction contained approximately 3.5 wt%
PVA, corresponding to approximately 800-mM uncharged vinyl
alcohol segments or approximately 50 segments per network
charge. Thus, since PVA is the main component of the bead
network, a favorable interaction with DOX is expected to promote
binding.
The third contribution takes into account that aggregation
inside the beads favors the deprotonated form of DOX, since pro-
tons are repelled by the positive electrostatic potential at the
aggregate surfaces. Thus, a substantial fraction may be uncharged
Figure 6. Curve ﬁtting of theoretical model of doxorubicin (DOX) release (presented as the mean value of 3 replicates) from beads in the free-ﬂowing method. In vitro release
proﬁles were collected in phosphate buffer saline (PBS), pH 7.4, 37C. Left panel shows the ﬁlm control model, (a) 70-150 mm, (c) 100-300 mm, and (e) 300-500 mm. Right panel
shows the internal depletion model, (b) 70-150 mm, (d) 100-300 mm, and (f) 300-500 mm.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-33983396inside the beads even at pH values where DOX is fully protonated in
the solution. The effect is expected to increase with decreasing
ionic strength (see the following section) anddsince loading is
performed in the absence of saltdit cannot be neglected a priori.
The factors discussed here are important for understanding the
release mechanism. As noted previously, the mechanism proposed
in the literature is based on ion exchange.6 Evidence in favor of it is
the observation that the maximum fraction released increases with
increasing concentration of salt in the release medium. Gonzalez
et al.5 found that the amount released from beads loaded with
25 mg/mL was negligible (approximately 0%) when 1 mL of beads
was transferred to 50 mL of pure water. However, even the
maximum fraction released in 50-mL PBS was only approximately
5%. After 24 hours in a solution of 250-mL NaCl, the fraction
released was only approximately 7%, 12%, 14%, and 28% at 77, 150,
770, and 1500 mM NaCl, respectively. Clearly salt has an effect, but
it is not strong, and the amount of salt available in the release
medium cannot be the limiting factor. On the other hand, the
maximum fraction released increased with increasing volume ofthe release medium, in line with our free-ﬂowing experiments
where the ﬁnal values reached 30%-40% in 140mMNaCl at a gel-to-
solution volume ratio of ca. 1:700 (Fig. 6). It appears that, above a
minimum salt concentration, increasing the volume of the release
medium has a greater effect on the fraction released than
increasing the salt concentration. We believe this is a consequence
of the high level of DOX loading in the release experiments.
The poor efﬁciency of salt as a release agent is understandable in
light of the behavior of surfactant-gel systems. In these systems, the
addition of high concentrations of salt actually promotes surfactant
binding when the charge ratio between surfactant and polymer in
the gels exceeds unity.51 The explanation is that salt reduces the
entropic cost of cobinding the surfactant counterions.54 However,
since the addition of salt actually increased the fraction of DOX
released, there must be other effects of salt in the present DDS. One
effect is on the equilibrium between protonated and deprotonated
DOX mentioned previously, and the other is the effect on the
aggregation of DOX in the solution. The PB cell model calculations
show that the DOX-to-polymer charge ratio inside the beads
Figure 7. Ratio between protonated DOX molecules and negative network charges
([þ]/[]), mole fraction protonated DOX in aggregates (Xþ), and fraction released DOX
at ionic strengths 10 and 100 mM (pH 7.4) calculated from the Poisson-Boltzmann cell
model, taking into account equilibrium between DOX monomers and dimers in the
solution; K ¼ 0 (10 mM), K ¼ 100 M1 (100 mM). A: Local equilibrium between bead
and solution before release of DOX. B: Equilibrium between bead and solution. Total
ratio between DOX molecules and negative network charges: 5.7; total DOX concen-
tration in system: 0.063 mM.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-3398 3397([þ]/[]) remains larger than unity but is considerably smaller than
what it would be with DOX fully protonated, which in case Awould
be 5.7. The calculations show that xDþ decreases with decreasing
salt concentration. Therefore, it follows from the conditions of
micelle equilibrium that also the equilibrium concentration of free
Dþ in the aqueous domains inside the beads decreases with
decreasing salt concentration. However, the net effect is to increase
the equilibrium concentration of DOX in the solution outside the
gels (not shown). This means that a larger fraction would be
released at 10 mM than at 100-mM salt before the concentration in
the solution reaches the level corresponding to equilibrium with
the beads. This is a general result when [þ]/[] >1, in agreement
with the effect of salt seen in surfactant-gel systems.50 Thus, our
conclusion is that charge regulation alone cannot explain why
increasing the salt concentration increases the maximum fraction
released in the experiments. However, the effect can be accounted
for, at least qualitatively, if dimerization occurs in the solution at
100 mM but not at 10-mM salt. According to the calculations where
the dimerization model was combined with the PB cell model, a
10-fold increase in salt concentration generates a 2-fold increase in
the maximum fraction released. These results suggest that the
mechanism is one in which salt increases the maximum fraction
released by facilitating aggregation of DOX in the solution. This
allows the total concentration released to increase to higher values
before the activity of DOX in the solution reaches a level corre-
sponding to equilibrium with the beads.
In futureworkwe intend to implement a thermodynamicmodel
with a model for the release kinetics, including charge regulation
effects andaggregation in the solution.However, Figure7 shows that
xDþ is nearly the same in cases A and B, meaning that the composi-
tion of the aggregates is largely independent of the loading level at a
given salt concentration. A constant composition of the micellesmeans that the concentration of free DOX in local equilibriumwith
micelles is constant. This favors the ﬁlm control and the internal
depletion-layer models since in both of them the equilibrium-free
concentration is assumed to be constant during the release process.
Conclusion
In conclusion, smaller beads (70-150 mm) have up to twice the
release rates of larger beads (100-300 and 300-500 mm), indicating
the crucial role of the available total surface area for drug release.
The temperature-dependent in vitro release demonstrated the
impact of viscosity and diffusion constant changes. Buffer strengths
of 10 mM decreased the released amount (Amax) of DOX with
70%-80% compared 100 mM. This is explainable, to some extent, by
the corresponding decrease of positively charged ions. The com-
bination of the 6-mm SR and 10-15 mL release medium described
the in vivo release most accurately. The in vitro release of DOX was
not inﬂuenced by pH, which indicates that the pH in the tumor
microenvironment would not much affect the drug release of DOX
from the beads in vivo. However, the inﬂuence of electrolytes on the
in vivo release remains to be investigated. The release mechanism
in the free-ﬂowing method was ﬁlm control, which was conﬁrmed
by the positive correlation between release rate and stirring rate for
all bead sizes. The theoretical release modeling also suggested that
the release of DOX from the beads was inﬂuenced by DOX-DOX
aggregates, DOX-PVA interactions, and the equilibrium between
protonated and deprotonated DOX. In addition, the available vol-
ume of release medium, potentially affecting the hydrodynamics
and diffusion at the target site, may have had a greater impact on
the release of DOX than that of the buffer strength. In future work,
we intend to implement a thermodynamic model with a model for
the release kinetics. This thermodynamicmodel will include charge
regulation effects and aggregation in the solution, as well as the
actual volume change of the beads.
Acknowledgments
Financial support was provided by the Swedish Research
Council, grant number 521-2011-373. The analysis of the sulfur
concentration was kindly performed by Jean Pettersson, Depart-
ment of Chemistry, Uppsala University.
References
1. Andhariya JV, Burgess DJ. Recent advances in testing of microsphere drug
delivery systems. Expert Opin Drug Deliv. 2016;13(4):593-608.
2. Shen J, Burgess DJ. In vitroein vivo correlation for complex non-oral drug
products: where do we stand? J Control Release. 2015;219:644-651.
3. Larsen C, Larsen SW, Jensen H, Yaghmur A, Ostergaard J. Role of in vitro release
models in formulation development and quality control of parenteral depots.
Expert Opin Drug Deliv. 2009;6(12):1283-1295.
4. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a
drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol.
2006;17(2 Pt 1):335-342.
5. Gonzalez MV, Tang Y, Phillips GJ, et al. Doxorubicin eluting beads-2: methods
for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater
Med. 2008;19(2):767-775.
6. Biondi M, Fusco S, Lewis AL, Netti PA. Investigation of the mechanisms gov-
erning doxorubicin and irinotecan release from drug-eluting beads: mathe-
matical modeling and experimental veriﬁcation. J Mater Sci Mater Med.
2013;24(10):2359-2370.
7. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of
chemoembolization loadable beads: in vitro drug release and physical prop-
erties of DC bead and hepasphere loaded with doxorubicin and irinotecan.
J Vasc Interv Radiol. 2010;21(7):1084-1090.
8. Dreher MR, Sharma KV, Woods DL, et al. Radiopaque drug-eluting beads for
transcatheter embolotherapy: experimental study of drug penetration and
coverage in swine. J Vasc Interv Radiol. 2012;23(2):257-264.e254.
9. Avdeef A, Tsinman O. Miniaturized rotating disk intrinsic dissolution rate
measurement: effects of buffer capacity in comparisons to traditional Wood’s
apparatus. Pharm Res. 2008;25(11):2613-2627.
E. Ahnfelt et al. / Journal of Pharmaceutical Sciences 105 (2016) 3387-3398339810. Ahnfelt E, Sj€ogren E, Axen N, Lennern€as H. A miniaturized in vitro release
method for investigating drug-release mechanisms. Int J Pharm. 2015;486(1-2):
339-349.
11. Brown CK, Friedel HD, Barker AR, et al. FIP/AAPS joint workshop report:
dissolution/in vitro release testing of novel/special dosage forms. AAPS
PharmSciTech. 2011;12(2):782-794.
12. Martinez M, Rathbone M, Burgess D, Huynh M. In vitro and in vivo consider-
ations associated with parenteral sustained release products: a review based
upon information presented and points expressed at the 2007 Controlled
Release Society Annual Meeting. J Control Release. 2008;129(2):79-87.
13. Zolnik BS, Burgess DJ. Evaluation of in vivoein vitro release of dexamethasone
from PLGA microspheres. J Control Release. 2008;127(2):137-145.
14. EASL-EORTC. Easleeortc clinical practice guidelines: management of hepato-
cellular carcinoma. J Hepatol. 2012;56(4):908-943.
15. Dubbelboer IR, Lilienberg E, Ahnfelt E, Sj€ogren E, Axen N, Lennern€as H.
Treatment of intermediate stage hepatocellular carcinoma: a review of intra-
hepatic doxorubicin drug-delivery systems. Ther Deliv. 2014;5(4):447-466.
16. Dalmark M. Characteristics of doxorubicin transport in human red blood cells.
Scand J Clin Lab Invest. 1981;41(7):633-639.
17. Lewis AL, Gonzalez MV, Leppard SW, et al. Doxorubicin eluting beads - 1:
effects of drug loading on bead characteristics and drug distribution. J Mater Sci
Mater Med. 2007;18(9):1691-1699.
18. LewisAL,HoldenRR.DCBeadembolicdrug-elutingbead: clinical application in the
locoregional treatment of tumours. Expert Opin Drug Deliv. 2011;8(2):153-169.
19. Lilienberg E, Ebeling Barbier C, Nyman R, et al. Investigation of hepatobiliary
disposition of doxorubicin following intrahepatic delivery of different dosage
forms. Mol Pharm. 2013;11(1):131-144.
20. Lilienberg E. Biopharmaceutical evaluation of intra-arterial drug-delivery systems
for liver cancer: investigations in healthy pigs and liver cancer patients; 2015.
Available at: www.diva-portal.org/smash/get/diva2:873356/FULLTEXT01.pdf.
Accessed June 30, 2016.
21. Bijlani V, Yuonayel D, Katpally S, Chukwumezie BN, Adeyeye MC. Monitoring
ibuprofen release from multiparticulates: in situ ﬁber-optic technique versus
the HPLC method: a technical note. AAPS PharmSciTech. 2007;8(3):E9-E12.
22. Avdeef A, Tsinman K, Tsinman O, Sun N, Voloboy D. Miniaturization of powder
dissolution measurement and estimation of particle size. Chem Biodivers.
2009;6(11):1796-1811.
23. Csuhai E, Kangarlou S, Xiang TX, et al. Determination of key parameters for a
mechanism-based model to predict doxorubicin release from actively loaded
liposomes. J Pharm Sci. 2014.
24. Shen J, Burgess DJ. Accelerated in vitro release testing of implantable PLGA
microsphere/PVA hydrogel composite coatings. Int J Pharm. 2012;422(1-2):
341-348.
25. Zolnik BS, Leary PE, Burgess DJ. Elevated temperature accelerated release
testing of PLGA microspheres. J Control Release. 2006;112(3):293-300.
26. Burton M, Chen Y, Atkinson H, Codde J, Jones S, Gray B. In vitro and in vivo
responses of doxorubicin ion exchange microspheres to hyperthermia. Int J
Hyperthermia. 1992;8(4):485-494.
27. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive
and active tumor targeting of nanocarriers for anti-cancer drug delivery.
J Control Release. 2010;148(2):135-146.
28. Ding H-M, Ma Y-Q. Controlling cellular uptake of nanoparticles with
pH-sensitive polymers. Sci Rep. 2013;3:1-6.
29. P€oyki€o R, Torvela H, Per€am€aki P, Kuokkanen T, R€onkk€om€aki H. Comparison of
dissolution methods for multi-element analysis of some plant materials used
as bioindicator of sulphur and heavy metal deposition determined. Analusis.
2000;28(9):850-854.
30. Biocompatibles UK LTD; 2016. http://bead.btg-im.com/. Accessed January 20,
2016.
31. Waters LJ, Swaine TS, Lewis AL. A calorimetric investigation of doxor-
ubicinepolymer bead interactions. Int J Pharm. 2015;493(1-2):129-133.32. Fül€op Z, Gref R, Loftsson T. A permeation method for detection of self-
aggregation of doxorubicin in aqueous environment. Int J Pharm.
2013;454(1):559-561.
33. Hayakawa E, Furuya K, Ueno H, Moriyama M, Kondo A. Visible absorption and
proton nuclear magnetic resonance studies on the self-association of doxoru-
bicin in aqueous solution. Chem Pharm Bull. 1991;39(4):1009-1012.
34. Coulson JM, Richardson JF, Backhurst JR, Harker JH. In: Coulson & Richardson's
Chemical Engineering. Oxford: Butterworth Heinemann; 1996.
35. Levins DM, Glastonbury JR. Particle-liquid hydrodynamics and mass transfer in
a stirred vessel. Part II e mass transfer. Trans Inst Chem Eng. 1972;50:132-146.
36. Fan L, Singh S. Controlled Release: A Quantitative Treatment. New York: Springer
Berlin; 1989.
37. Helfferich FG. Ion Exchange. Courier Corporation. New York, NY: McGraw-Hill;
1962.
38. Higuchi T. Rate of release of medicaments from ointment bases containing
drugs in suspension. J Pharm Sci. 1961;50(10):874-875.
39. J€onsson B, Wennerstr€om H. Phase equilibria in a three-component water-soap-
alcohol system. A thermodynamic model. J Phys Chem. 1987;91(2):338-352.
40. Li X, Hirsh DJ, Cabral-Lilly D, et al. Doxorubicin physical state in solution and
inside liposomes loaded via a pH gradient. Biochim Biophys Acta. 1998;1415(1):
23-40.
41. Menozzi M, Valentini L, Vannini E, Arcamone F. Self-association of doxorubicin
and related compounds in aqueous solution. J Pharm Sci. 1984;73(6):766-770.
42. Carugo D, Capretto L, Roy B, et al. Spatiotemporal dynamics of doxorubicin
elution from embolic beads within a microﬂuidic network. J Control Release.
2015;214:62-75.
43. Schreier S, Malheiros SVP, de Paula E. Surface active drugs: self-association and
interaction with membranes and surfactants. Physicochemical and biological
aspects. Biochim Biophys Acta. 2000;1508(1-2):210-234.
44. Agrawal P, Barthwal SK, Barthwal R. Studies on self-aggregation of anthracy-
cline drugs by restrained molecular dynamics approach using nuclear mag-
netic resonance spectroscopy supported by absorption, ﬂuorescence, diffusion
ordered spectroscopy and mass spectrometry. Eur J Med Chem. 2009;44(4):
1437-1451.
45. Biondi M, Fusco S, Lewis AL, Netti PA. New insights into the mechanisms of the
interactions between doxorubicin and the ion-exchange hydrogel DC Bead for
use in transarterial chemoembolization (TACE). J Biomater Sci Polym Ed.
2012;23(1-4):333-354.
46. Dalmark M, Storm H. A Fickian diffusion transport process with features of
transport catalysis. Doxorubicin transport in human red blood cells. J Gen
Physiol. 1981;78(4):349-364.
47. Boyd G, Adamson A, Myers Jr L. The exchange adsorption of ions from aqueous
solutions by organic zeolites. II. Kinetics1. J Am Chem Soc. 1947;69(11):2836-
2848.
48. Bhaskar R, Murthy R, Miglani B, Viswanathan K. Novel method to evaluate
diffusion controlled release of drug from resinate. Int J Pharm. 1986;28(1):59-66.
49. Hansson P. Self-assembly of ionic surfactants in polyelectrolyte solutions: a
model for mixtures of opposite charge. Langmuir. 2001;17(14):4167-4180.
50. Hansson P. Interaction between polyelectrolyte gels and surfactants of oppo-
site charge. Curr Opinion Colloid Interface Sci. 2006;11(6):351-362.
51. Mironov AV, Starodoubtsev SG, Khokhlov AR, Dembo AT, Dembo KA. Effect of
chemical nature of 1, 1-salt on structure of polyelectrolyte gel-surfactant
complexes. J Phys Chem B. 2001;105(24):5612-5617.
52. Shirahama K, Himuro A, Takisawa N. Binding of hexadecylammonium sur-
factants to water-soluble neutral polymers. Colloid Polym Sci. 1987;265(2):
96-100.
53. Tadros TF. The interaction of cetyltrimethylammonium bromide and sodium
dodecylbenzene sulfonate with polyvinyl alcohol. adsorption of the polymer-
dsurfactant complexes on silica. J Colloid Interf Sci. 1974;46(3):528-540.
54. Hansson P. Surfactant self-assembly in oppositely charged polymer networks.
Theory. J Phys Chem B. 2009;113(39):12903-12915.
